CeriBell (CBLL) Q4 2025 Earnings Call Transcript
The Motley Fool
by newsfeedback@fool.com (Motley Fool Transcribing)February 24, 2026
AI-Generated Deep Dive Summary
CeriBell (CBLL) delivered strong financial results in its Q4 2025 earnings call, highlighted by a 34% year-over-year increase in quarterly revenue to $24.8 million and an impressive 36% growth to $89.1 million for the full year. The company’s gross margin remained robust at 87% for the quarter and 88% for the year, with expectations for mid-80% margins in 2026 despite ongoing tariff and cost challenges. Revenue diversification was a key driver of growth, with products revenue surging 33% to $18.8 million and subscription revenue jumping 37% to $6.0 million in the quarter alone.
The company also demonstrated significant progress in market expansion, increasing its total addressable market (TAM) to $3.5 billion following FDA clearances for neonate/pediatric seizure monitoring and delirium algorithm approvals. This growth was further supported by a 4% penetration rate in its core $2.5 billion seizure opportunity and strong system-level adoption strategies at hospital networks. CeriBell’s commercial infrastructure expanded, adding territories to reach 55 locations by year-end, with plans for further investment to accelerate account acquisition.
However, operating expenses rose sharply, increasing 24% to $36.2 million in the quarter and 42% to $136.7 million annually, driven by commercial investments, headcount growth, and legal costs. The net loss for the year totaled $53.4 million, reflecting the impact of these expenses. Despite this, CeriBell maintained a strong cash position of $159.3 million, providing a solid foundation for future growth and strategic initiatives.
CeriBell’s Q4 2025 results underscore its ability to capitalize on market opportunities while navigating regulatory challenges. The company’s focus on expanding its product portfolio, increasing market penetration, and improving commercial infrastructure positions it as a key player in the medical technology sector.
Verticals
financeinvesting
Originally published on The Motley Fool on 2/24/2026